Thalidomide is a drug that was widely prescribed in the late 1950s and early 1960s as a sedative and to treat morning sickness in pregnant women. It has one chiral centre, giving rise to two enantiomers:
The drug was originally marketed as a racemic mixture (an equimolar 50:50 mixture of both enantiomers), which led to tragic birth defects in thousands of children worldwide.
A racemic mixture (racemate) is an equimolar mixture of the two enantiomers of a chiral compound. Because the - and -forms rotate plane-polarised light by equal but opposite amounts, the rotations cancel and the mixture is optically inactive (net rotation = ).
The two enantiomers of a chiral drug can have completely different biological activities because biological receptors (enzymes, proteins) are themselves chiral — they interact differently with each enantiomer, like a hand fitting into a glove. In the case of Thalidomide:
| Enantiomer | Biological Effect |
|---|---|
| -Thalidomide | Safe sedative / anti-nausea |
| -Thalidomide | Teratogenic (causes birth defects) |
This illustrates the significance of chirality in pharmaceutical chemistry: administering a racemic mixture means the patient receives both a beneficial and a harmful compound.
Chiral resolution is the process of separating a racemic mixture into its individual pure enantiomers.
This is the most common chemical method:
Key principle: Enantiomers have identical physical properties and cannot be separated by ordinary physical methods. Converting them to diastereomers gives compounds with different properties that can be separated.
The racemic mixture is passed through a column packed with a chiral stationary phase. Each enantiomer interacts differently with the chiral packing material and elutes at a different rate, allowing separation.
Even if pure -Thalidomide is administered to a patient, the -isomer still appears in the bloodstream. This is because Thalidomide undergoes in vivo racemization:
This means that for Thalidomide specifically, simply separating the enantiomers does not eliminate the teratogenic risk.
A more elegant solution to the problem of racemic mixtures in drug synthesis is to use a chiral catalyst (asymmetric synthesis):
| Concept | Key Point |
|---|---|
| Racemic mixture | 50:50 mixture of enantiomers; optically inactive |
| Thalidomide tragedy | -form is teratogenic; -form is safe |
| Chiral resolution | Separation via diastereomers or chiral chromatography |
| In vivo racemization | -Thalidomide converts to -form in the body |
| Chiral catalysts | Produce a single enantiomer directly; avoid racemate |